Probiotics and Allergic Diseases

The main purpose: To investigate if Lactobacillus paracasei GMNL-133(LP), Lactobacillus fermentum GM-090(LF), Lactobacillus paracasei GMNL-133 (LP) with Lactobacillus fermentum GM-090 (LF) combination products could be used for the adjuvant treatment of atopic dermatitis and asthma.

The Secondary Objective: To investigate whether probiotics consumption improve the quality of life and allergic symptoms to different people with Lactobacillus paracasei GMNL-133 (LP), Lactobacillus fermentum GM-090 (LF) and Lactobacillus paracasei GMNL-133(LP) and Lactobacillus fermentum GM-090 (LF) combination products.

Inclusion criteria

• Age between 1 year old and 18 years old,
• AD cases fulfill the diagnostic criteria by Hannifin and Rajka.
• Atopy as shown by at least one positive skin test (weal size ≧ 3mm) or one positive MAST (RAST) (IgE ≧ 0.7 kU/L) test to any common food or environmental allergens.

Exclusion criteria

• Systematic corticosteroid, immunosuppressive therapy, or antimycotics treatment during the 4 weeks, antihistamines, and singulair during the 7 days before enrollment
• Probiotic preparations used within 2 weeks before entering the study
• Use of antibiotics now or other oral medications that will interfere the results
• If they had immune deficiency disease or other major medical problems
• If they had participated in another clinical study during the past month.
• Subjects are undergoing desensitization therapy within 3 months prior to the screening period.
• Subjects have participated investigational drug trial within 4 weeks before entering this study.
• Subjects are pregnant, lactating or planning to become pregnant.
• Subjects with any other serious diseases considered by the investigator that could interfere with the performance of SCORAD score result.
• Subjects who is lack of physical integrity of gastrointestinal tract, or malabsorption syndrome, or inability to take oral medication.